MX375794B - Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. - Google Patents

Axitinib para usarse en el tratamiento de cáncer de células renales metastásico.

Info

Publication number
MX375794B
MX375794B MX2016013910A MX2016013910A MX375794B MX 375794 B MX375794 B MX 375794B MX 2016013910 A MX2016013910 A MX 2016013910A MX 2016013910 A MX2016013910 A MX 2016013910A MX 375794 B MX375794 B MX 375794B
Authority
MX
Mexico
Prior art keywords
axitinib
treatment
renal cell
cell cancer
metastatic renal
Prior art date
Application number
MX2016013910A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013910A (es
Inventor
Jamal Christo Tarazi
James Andrew Williams
Jean- Francois Andre MARTINI
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016013910A publication Critical patent/MX2016013910A/es
Publication of MX375794B publication Critical patent/MX375794B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
MX2016013910A 2014-04-24 2015-04-16 Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. MX375794B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (2)

Publication Number Publication Date
MX2016013910A MX2016013910A (es) 2017-01-11
MX375794B true MX375794B (es) 2025-03-07

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013910A MX375794B (es) 2014-04-24 2015-04-16 Axitinib para usarse en el tratamiento de cáncer de células renales metastásico.

Country Status (23)

Country Link
US (2) US20170184602A1 (enExample)
EP (1) EP3134119B1 (enExample)
JP (1) JP6603474B2 (enExample)
KR (1) KR101943177B1 (enExample)
CN (1) CN106233143B (enExample)
AR (1) AR100169A1 (enExample)
AU (3) AU2015249513A1 (enExample)
BR (1) BR112016024143A2 (enExample)
CA (1) CA2946362C (enExample)
CY (1) CY1120731T1 (enExample)
DK (1) DK3134119T3 (enExample)
ES (1) ES2691213T3 (enExample)
HU (1) HUE040167T2 (enExample)
IL (1) IL247859B (enExample)
MX (1) MX375794B (enExample)
PL (1) PL3134119T3 (enExample)
PT (1) PT3134119T (enExample)
RU (1) RU2651469C1 (enExample)
SG (1) SG11201607918TA (enExample)
SI (1) SI3134119T1 (enExample)
TR (1) TR201815682T4 (enExample)
TW (1) TWI568439B (enExample)
WO (1) WO2015162532A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
WO2020014666A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
US11409549B2 (en) 2018-10-15 2022-08-09 AIble Inc. Interface for generating models with customizable interface configurations
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US12656349B2 (en) 2019-10-17 2026-06-16 Board Of Regents, The University Of Texas System Measurement of bevacizumab-insensitive vascular endothelial growth factor-a
JP2025518482A (ja) * 2022-05-11 2025-06-17 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
CA3252723A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF A REP PROTEIN BMMF1 AS A DIAGNOSTIC MARKER FOR LUNG CANCER
EP4562058A4 (en) * 2022-07-28 2026-08-19 Univ Oklahoma BIOMARKERS, DIAGNOSTIC METHODS, TREATMENTS AND THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES AND DISORDERS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509613A (ja) 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
BRPI0715062A2 (pt) * 2006-07-28 2013-06-04 Novartis Ag mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma
EP2088863A2 (en) * 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
SG10201403896XA (en) * 2009-07-08 2014-10-30 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
KR101557545B1 (ko) * 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
AU2012318618B2 (en) * 2011-10-04 2017-01-12 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Also Published As

Publication number Publication date
KR101943177B1 (ko) 2019-01-28
US20190331687A1 (en) 2019-10-31
CA2946362C (en) 2019-03-12
HUE040167T2 (hu) 2019-02-28
JP2015210268A (ja) 2015-11-24
BR112016024143A2 (pt) 2017-08-15
CY1120731T1 (el) 2019-12-11
AU2020200237A1 (en) 2020-02-06
HK1231561A1 (zh) 2017-12-22
AU2018203086A1 (en) 2018-05-24
SG11201607918TA (en) 2016-11-29
ES2691213T3 (es) 2018-11-26
MX2016013910A (es) 2017-01-11
JP6603474B2 (ja) 2019-11-06
DK3134119T3 (en) 2018-10-22
RU2651469C1 (ru) 2018-04-19
CN106233143B (zh) 2020-01-21
AR100169A1 (es) 2016-09-14
WO2015162532A1 (en) 2015-10-29
CN106233143A (zh) 2016-12-14
CA2946362A1 (en) 2015-10-29
TR201815682T4 (tr) 2018-11-21
PL3134119T3 (pl) 2018-12-31
TW201545747A (zh) 2015-12-16
AU2015249513A1 (en) 2016-10-06
SI3134119T1 (sl) 2018-11-30
KR20160134817A (ko) 2016-11-23
IL247859A0 (en) 2016-11-30
PT3134119T (pt) 2018-11-07
EP3134119A1 (en) 2017-03-01
IL247859B (en) 2020-07-30
EP3134119B1 (en) 2018-08-22
TWI568439B (zh) 2017-02-01
US20170184602A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CY1120731T1 (el) Θεραπευτικη αγωγη κατα του καρκινου
Harouaka et al. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
IL270974A (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
IL254639A0 (en) Digital analysis of cancer cells moving in the bloodstream in blood samples
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2018009254A (es) Metodos para evaluar el riesgo de desarrollar cancer colorrectal.
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
IL245766A0 (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)
EP4235179C0 (en) KIT FOR DETECTION, QUANTIFICATION AND/OR ISOLATION OF CIRCULATING TUMOR CELLS BASED ON CD321 MARKER EXPRESSION
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
MX381238B (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de células madre cancerosas.
EA201992875A1 (ru) T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения
WO2016018524A8 (en) E2f4 signature for use in diagnosing and treating breast and bladder cancer
EA201890816A1 (ru) Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли

Legal Events

Date Code Title Description
FG Grant or registration